And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Eczema

Advances in Treating Pediatric Inflammatory Skin Diseases thumbnail
Play Button

Advances in Treating Pediatric Inflammatory Skin Diseases

Series: Maui Derm for Dermatologists 2020 | February 12, 2020

From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis. 

Watch Video
Updates in Pediatric Dermatology thumbnail
Play Button

Updates in Pediatric Dermatology

Series: Maui Derm for Dermatologists 2020 | January 28, 2020

2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.

Watch Video
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates thumbnail
Play Button

DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates

Series: DermWire TV | January 21, 2020

On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.

Watch Video
DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD thumbnail
Play Button

DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD

Series: DermWire TV | December 12, 2019

New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic dermatitis.

Watch Video

News | October 18, 2019

Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PA

New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV)...

Read More

Advertisement

The Latest in Eczema

VIDEO | February 12, 2020

Advances in Treating Pediatric Inflammatory Skin Diseases

Meeting Coverage | Maui Derm for Dermatologists 2020

Maui, HI: January 25 - 29, 2020

Lawrence Eichenfield, MD, FAAD

Advertisement

VIDEO | January 28, 2020

Updates in Pediatric Dermatology

Meeting Coverage | Maui Derm for Dermatologists 2020

Maui, HI: January 25 - 29, 2020

Sheila Fallon-Friedlander, MD

VIDEO | January 13, 2020

Aloha Maui Derm

Meeting Coverage | Maui Derm for Dermatologists 2020

Maui, HI: January 25 - 29, 2020

George Martin, MD; and Joel L. Cohen, MD, FAAD

View more